How One Organization is Helping Patients with Blood Cancers Through the COVID-19 Pandemic

Video

Patients with blood cancers are facing unprecedented challenges to their treatment journeys as the COVID-19 pandemic continues to disrupt the cancer landscape. Which is why the Leukemia and Lymphoma Society is looking to offer its own lifeline to patients.

As the COVID-19 pandemic continues to impact the country, patients with blood cancers face treatment access issues and are experiencing isolation like never before. However, organizations like the Leukemia and Lymphoma Society (LLS) are there to offer a lifeline.

Recently, CURE® spoke with Dr. Gwen Nichols, the chief medical officer of the LLS about what the society is doing to help this patient population address their unique needs, by providing resources via their Webinars and Weekly Chats, among other things.

“For many blood cancer patients, these are really life-prolonging and potentially curative therapies that they need to get,” Nichols said. “So, we’re trying to be sure we help patients find the safest place to get their treatment.”

For the LLS, Nichols explained, this may mean traveling to an out-of-network office, which presents new problems that the organization is working to solve.

“We’re advocating for insurers to be more flexible about, for instance, if you need to go to a different office, that office might not be under your plan. Patients are frantic because they can’t pay that out-of-pocket or out-of-network cost. I think this will show us some ways the system is failing for cancer patients and ways we have to change to adapt to exactly this kind of problem.”

Nichols also discussed how this patient population can stay safe and manage their everyday life through the pandemic.

“I think being as educated as you can about what’s reality and what’s not is the most important thing you can do for your physical and your mental health,” she said.

Moreover, if patients are feeling overwhelmed or need assistance, patients and caregivers should reach out to the organization’s Information Specialists: master's level oncology professionals who provide free, personalized assistance to patients, families and healthcare providers, by calling (800) 955-4572 from Monday to Friday, 9 a.m. to 9 p.m. ET.

Related Videos
Jessica McDade, B.S.N., RN, OCN, in an interview with CURE
For patients with cancer, the ongoing chemotherapy shortage may cause some anxiety as they wonder how they will receive their drugs. However, measuring drugs “down to the minutiae of the milligrams” helped patients receive the drugs they needed, said Alison Tray. Tray is an advanced oncology certified nurse practitioner and current vice president of ambulatory operations at Rutgers Cancer Institute in New Jersey.  If patients are concerned about getting their cancer drugs, Tray noted that having “an open conversation” between patients and providers is key.  “As a provider and a nurse myself, having that conversation, that reassurance and sharing the information is a two-way conversation,” she said. “So just knowing that we're taking care of you, we're going to make sure that you receive the care that you need is the key takeaway.” In June 2023, many patients were unable to receive certain chemotherapy drugs, such as carboplatin and cisplatin because of an ongoing shortage. By October 2023, experts saw an improvement, although the “ongoing crisis” remained.  READ MORE: Patients With Lung Cancer Face Unmet Needs During Drug Shortages “We’re really proud of the work that we could do and achieve that through a critical drug shortage,” Tray said. “None of our patients missed a dose of chemotherapy and we were able to provide that for them.” Tray sat down with CURE® during the 49th Annual Oncology Nursing Society Annual Congress to discuss the ongoing chemo shortage and how patients and care teams approached these challenges. Transcript: Particularly at Hartford HealthCare, when we established this infrastructure, our goal was to make sure that every patient would get the treatment that they need and require, utilizing the data that we have from ASCO guidelines to ensure that we're getting the optimal high-quality standard of care in a timely fashion that we didn't have to delay therapies. So, we were able to do that by going down to the minutiae of the milligrams on hand, particularly when we had a lot of critical drug shortages. So it was really creating that process to really ensure that every patient would get the treatment that they needed. For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.
Dr. Andrea Apolo in an interview with CURE
Dr. Kim in an interview with CURE
Dr. Nguyen, from Stanford Health, in an interview with CURE
Dr. Barzi in an interview with CURE